Julie R Gralow1, William E Barlow2, Alexander H G Paterson3, Jieling L M'iao2, Danika L Lew2, Alison T Stopeck4, Daniel F Hayes5, Dawn L Hershman, Mark M Schubert6, Mark Clemons7, Catherine H Van Poznak, Elizabeth C Dees8, James N Ingle9, Carla I Falkson10, Anthony D Elias11, Michael J Messino12, Jeffrey H Margolis13, Shaker R Dakhil14, Helen K Chew15, Kim Z Dammann1, Jeffrey S Abrams16, Robert B Livingston17, Gabriel N Hortobagyi18. 1. University of Washington, Seattle, WA. 2. SWOG Statistical Center, Seattle, WA. 3. Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada. 4. Stony Brook Cancer Center, Stony Brook University Cancer Center, Stony Brook, NY. 5. University of Michigan, Ann Arbor, MI (DFH, CHVP); Columbia University, New York, NY. 6. Fred Hutchinson Cancer Research Center, Seattle, WA. 7. Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada. 8. University of North Carolina, Chapel Hill, NC. 9. Mayo Clinic, Rochester, MN. 10. University of Alabama, Birmingham, AL. 11. University of Colorado, Denver, CO. 12. Cancer Care of WNC, Greenville, NC. 13. Beaumont NCORP/William Beaumont Hospital, Royal Oak, MI. 14. Wichita NCORP, Wichita, KS. 15. University of California at Davis, Sacramento, CA. 16. Cancer Therapy and Evaluation Program, National Cancer Institute, Bethesda, MD. 17. University of Arizona, Tucson, AZ. 18. The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
BACKGROUND:Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates in postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Oncology study S0307 compared the efficacy of three bisphosphonates in early-stage breast cancer. METHODS:Patients with stageI-III breast cancer were randomly assigned to 3 years of intravenous zoledronic acid, oral clodronate, or oral ibandronate. The primary endpoint was disease-free survival (DFS) with overall survival as a secondary outcome. All statistical tests were two-sided. RESULTS: A total of 6097 patients enrolled. Median age was 52.7 years. Prior to being randomly assigned, 73.2% patients indicated preference for oral vs intravenous formulation. DFS did not differ across arms in a log-rank test (P = .49); 5-year DFS was 88.3% (zoledronic acid: 95% confidence interval [CI] = 86.9% to 89.6%), 87.6% (clodronate: 95% CI = 86.1% to 88.9%), and 87.4% (ibandronate: 95% CI = 85.6% to 88.9%). Additionally, 5-year overall survival did not differ between arms (log rank P = .50) and was 92.6% (zoledronic acid: 95% CI = 91.4% to 93.6%), 92.4% (clodronate: 95% CI = 91.2% to 93.5%), and 92.9% (ibandronate: 95% CI = 91.5% to 94.1%). Bone as first site of recurrence did not differ between arms (P = .93). Analyses based on age and tumor subtypes showed no treatment differences. Grade 3/4 toxicity was 8.8% (zoledronic acid), 8.3% (clodronate), and 10.5% (ibandronate). Osteonecrosis of the jaw was highest for zoledronic acid (1.26%) compared with clodronate (0.36%) and ibandronate (0.77%). CONCLUSIONS: We found no evidence of differences in efficacy by type of bisphosphonate, either in overall analysis or subgroups. Despite an increased rate of osteonecrosis of the jaw with zoledronic acid, overall toxicity grade differed little across arms. Given that patients expressed preference for oral formulation, efforts to make oral agents available in the United States should be considered.
RCT Entities:
BACKGROUND: Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates in postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Oncology study S0307 compared the efficacy of three bisphosphonates in early-stage breast cancer. METHODS:Patients with stage I-III breast cancer were randomly assigned to 3 years of intravenous zoledronic acid, oral clodronate, or oral ibandronate. The primary endpoint was disease-free survival (DFS) with overall survival as a secondary outcome. All statistical tests were two-sided. RESULTS: A total of 6097 patients enrolled. Median age was 52.7 years. Prior to being randomly assigned, 73.2% patients indicated preference for oral vs intravenous formulation. DFS did not differ across arms in a log-rank test (P = .49); 5-year DFS was 88.3% (zoledronic acid: 95% confidence interval [CI] = 86.9% to 89.6%), 87.6% (clodronate: 95% CI = 86.1% to 88.9%), and 87.4% (ibandronate: 95% CI = 85.6% to 88.9%). Additionally, 5-year overall survival did not differ between arms (log rank P = .50) and was 92.6% (zoledronic acid: 95% CI = 91.4% to 93.6%), 92.4% (clodronate: 95% CI = 91.2% to 93.5%), and 92.9% (ibandronate: 95% CI = 91.5% to 94.1%). Bone as first site of recurrence did not differ between arms (P = .93). Analyses based on age and tumor subtypes showed no treatment differences. Grade 3/4 toxicity was 8.8% (zoledronic acid), 8.3% (clodronate), and 10.5% (ibandronate). Osteonecrosis of the jaw was highest for zoledronic acid (1.26%) compared with clodronate (0.36%) and ibandronate (0.77%). CONCLUSIONS: We found no evidence of differences in efficacy by type of bisphosphonate, either in overall analysis or subgroups. Despite an increased rate of osteonecrosis of the jaw with zoledronic acid, overall toxicity grade differed little across arms. Given that patients expressed preference for oral formulation, efforts to make oral agents available in the United States should be considered.
Authors: Michael Gnant; Georg Pfeiler; Peter C Dubsky; Michael Hubalek; Richard Greil; Raimund Jakesz; Viktor Wette; Marija Balic; Ferdinand Haslbauer; Elisabeth Melbinger; Vesna Bjelic-Radisic; Silvia Artner-Matuschek; Florian Fitzal; Christian Marth; Paul Sevelda; Brigitte Mlineritsch; Günther G Steger; Diether Manfreda; Ruth Exner; Daniel Egle; Jonas Bergh; Franz Kainberger; Susan Talbot; Douglas Warner; Christian Fesl; Christian F Singer Journal: Lancet Date: 2015-05-31 Impact factor: 79.321
Authors: Alexander H G Paterson; Stewart J Anderson; Barry C Lembersky; Louis Fehrenbacher; Carla I Falkson; Karen M King; Lorna M Weir; Adam M Brufsky; Shaker Dakhil; Thomas Lad; Luis Baez-Diaz; Julie R Gralow; André Robidoux; Edith A Perez; Ping Zheng; Charles E Geyer; Sandra M Swain; Joseph P Costantino; Eleftherios P Mamounas; Norman Wolmark Journal: Lancet Oncol Date: 2012-06-14 Impact factor: 41.316
Authors: Robert Coleman; Andrew Hall; Joan Albanell; Andrew Hanby; Richard Bell; David Cameron; David Dodwell; Helen Marshall; Joël Jean-Mairet; Juan-Carlos Tercero; Federico Rojo; Walter Gregory; Roger R Gomis Journal: Lancet Oncol Date: 2017-10-13 Impact factor: 41.316
Authors: P Hadji; M S Aapro; J J Body; N J Bundred; A Brufsky; R E Coleman; M Gnant; T Guise; A Lipton Journal: Ann Oncol Date: 2011-03-17 Impact factor: 32.976
Authors: Michael Gnant; Brigitte Mlineritsch; Gero Luschin-Ebengreuth; Franz Kainberger; Helmut Kässmann; Jutta Claudia Piswanger-Sölkner; Michael Seifert; Ferdinand Ploner; Christian Menzel; Peter Dubsky; Florian Fitzal; Vesna Bjelic-Radisic; Günther Steger; Richard Greil; Christian Marth; Ernst Kubista; Hellmut Samonigg; Peter Wohlmuth; Martina Mittlböck; Raimund Jakesz Journal: Lancet Oncol Date: 2008-08-19 Impact factor: 41.316
Authors: Sharon McGee; Mashari AlZahrani; Carol Stober; Terry L Ng; Katherine Cole; Gail Larocque; Arif Awan; Sandeep Sehdev; John Hilton; Lisa Vandermeer; Brian Hutton; Gregory Pond; Deanna Saunders; Mark Clemons Journal: J Bone Oncol Date: 2021-02-19 Impact factor: 4.072
Authors: Komal Waqas; Joana Lima Ferreira; Elena Tsourdi; Jean-Jacques Body; Peyman Hadji; M C Zillikens Journal: J Bone Oncol Date: 2021-03-18 Impact factor: 4.072
Authors: Alexander H G Paterson; Peter C Lucas; Stewart J Anderson; Eleftherios P Mamounas; Adam Brufsky; Luis Baez-Diaz; Karen M King; Thomas Lad; André Robidoux; Melanie Finnigan; Miguel Sampayo; Juan Carlos Tercero; Joël Jean Mairet; Antonio C Wolff; Louis Fehrenbacher; Norman Wolmark; Roger R Gomis Journal: JNCI Cancer Spectr Date: 2021-05-28
Authors: Darya A Kizub; Jieling Miao; Mark M Schubert; Alexander H G Paterson; Mark Clemons; Elizabeth C Dees; James N Ingle; Carla I Falkson; William E Barlow; Gabriel N Hortobagyi; Julie R Gralow Journal: Support Care Cancer Date: 2020-09-15 Impact factor: 3.603